The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
Open accessAbstract
Background and Aims Studies are needed to determine the long-term effects of bariatric surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver samples, collected the time of bariatric surgery and 1 and 5 years later, to assess the long-term effects of bariatric surgery in patients with NASH. Methods We performed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical research network histologic scores. The patients underwent bariatric surgery at a single center in France and were followed for 5 years. We obtained liver samples from 125 of 169 patients (76%) having reached 1 year and 64 of 94 patients (68%) having reached 5 years after surgery. The primary endpoint was the resolution of NASH without worsening of fibrosis at 5 years. Secondary end points were improvement in fibrosis (reduction of ≥1 stage) at 5 years and regression of fibrosis and NASH at 1 and 5 years. Results At 5 years after bariatric surgery, NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval, 73.1%-92.2%). Fibrosis decreased, compared with baseline, in samples from 70.2% of patients (95% CI, 56.6%-81.6%). Fibrosis disappeared from samples from 56% of all patients (95% CI, 42.4%-69.3%) and from samples from 45.5% of patients with baseline bridging fibrosis. Persistence of NASH was associated with no decrease in fibrosis and less weight loss (reduction in body mass index of 6.3 ± 4.1 kg/m 2 in patients with persistent NASH vs reduction of 13.4 ± 7.4 kg/m 2 ; P = .017 with resolution of NASH). Resolution of NASH was observed at 1 year after bariatric surgery in biopsies from 84% of patients, with no significant recurrence between 1 and 5 years ( P = .17). Fibrosis began to decrease by 1 year after surgery and continued to decrease until 5 years ( P < .001). Conclusions In a long-term follow-up of patients with NASH who underwent bariatric surgery, we observed resolution of NASH in liver samples from 84% of patients 5 years later. The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an observational study, MASH was resolved in 84% of 180 individuals with class 2 obesity and MASH 5 years after Roux-en-Y gastric bypass (66%), sleeve gastrectomy (12%) or gastric banding (22%).”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [443]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Pioglitazone therapy, GLP-1 RA therapy, and metabolic surgery have all been shown to reduce NASH activity; pioglitazone therapy and metabolic surgery may also improve hepatic fi brosis (188,292 -298).”
The cited source says what the claim attributes to it.
In the citing paper
“One of the most promising developments in the field is the growing consensus that liver fibrosis can be a reversible process under certain conditions, particularly if the underlying cause of injury is removed (84–86).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“Procedures like Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) are associated with significant metabolic improvements and reductions in NAFLD severity [13,14,15], including reductions in liver fat, liver enzymes, and fibrosis [16,17,18].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [16]
In the citing paper
“The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years [4,127].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [127]
In the citing paper
“In a long-term follow-up study of patients with MASH who underwent bariatric surgery, the resolution of MASH in liver samples was observed from 84% of patients 5 years later.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [127]
In the citing paper
“Weight loss either through lifestyle intervention68 or bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy)69,70 improves the lipid profile by reducing total TAGs, and increasing PC, PE and HDL concentrations.125”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [70]
In the citing paper
“Nevertheless, these interventions suggest that, like HCV and HBV, MASH fibrosis is reversible in non-cirrhotic liver, but unlike in HCV and HBV there is no evidence yet that cirrhosis in MASH is reversible (259).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [259]
In the citing paper
“Wound healing in the liver is dynamic and reversible,105 with ample evidence of fibrosis regression after effective treatment of viral hepatitis, and even following bariatric surgery in patients with NASH.106”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 620
Lan, Y., & Wang, L. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.09.008
Mathurin, P., Dharancy, S., & Lassailly, G. (2021) · Elsevier eBooks · doi:10.1016/b978-2-294-76753-1.00050-3
Self-citationMICROWAVE SPECTRUM AND STRUCTURE OF 2-CHLOROPROPIONITRILE
Ogata, T., & Yamashita, N. (1995) · The Knowledge Bank (The Ohio State University)
NASH y cirugía metabólica: cuando tienes los datos pero no puedes demostrarlo
Balibrea, J. M., & Turrado-Rodriguez, V. (2021) · Cirugía Española · doi:10.1016/j.ciresp.2021.11.016
Sanyal, A. J., Chung, C., Myers, R. P., & Bosch, J. (2022) · Hepatology · doi:10.1002/hep.32373
Patient Selection in Bariatric Surgery
Sarkar, R. (2021) · Springer eBooks · doi:10.1007/978-3-030-54064-7_8-1
Metabolic surgery and NASH: When you have the data but you can’t prove it
Balibrea, J. M., & Turrado-Rodriguez, V. (2022) · Cirugía Española (English Edition) · doi:10.1016/j.cireng.2022.02.015
Ratziu, V. (2022) · Hepatology · doi:10.1002/hep.32515
Impact of Metabolic and Bariatric Surgery on Liver Diseases
Agarwal, L., Chekuri, R., Singla, V., Kumar, A., Shalimar, S., & Aggarwal, S. (2022) · Journal of Bariatric Surgery · doi:10.4103/jbs.jbs_9_22
Stroh, C., & Luderer, D. (2022) · Allgemein- und Viszeralchirurgie up2date · doi:10.1055/a-1652-4605
Effect of Metabolic Surgery on Non-Alcoholic Steatohepatitis
Fearon, N. M., & Pournaras, D. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-54064-7_107-1
Leberfibrose - Diagnostik und innovative Therapieansätze
Roehlen, N., Thimme, R., & Böttler, T. (2022) · Gastro-News · doi:10.1007/s15036-022-3108-8
Therapies for Alcohol-Related Liver Disease and for Non-Alcoholic Fatty Liver Disease
Yoshiji, H., Namisaki, T., Kaji, K., & Francque, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-08552-9_19
Laparoscopic Sleeve Gastrectomy: Comorbidity Outcomes
Felsenreich, D. M., & Prager, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-60596-4_86
Alexandre, F., Lapergola, A., Vannucci, M., Pizzicannella, M., D’Urso, A., Saviano, A., Mutter, D., Vix, M., & Perretta, S. (2023) · Journal de Chirurgie Viscérale · doi:10.1016/j.jchirv.2022.12.003
Non-alcoholic Steatohepatitis: Global Impact and Clinical Consequences
Younossi, Z. M., & Henry, L. L. (2022) · EMJ Hepatology · doi:10.33590/emjhepatol/22-00150 · Cited by 1
Metabolic-associated fatty liver disease: pharmacological management
Shi, Y., & Fan, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00010-0
Rapport 23-02. Le foie stéatosique non alcoolique : un défi de santé publique
Brissot, P., & Buffet, C. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.03.014
NASH et chirurgie de l’obésité
Leray, M., Lassailly, G., & Pattou, F. N. (2023) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.12.002
Self-citationFredrickson, G., Florczak, K. L., Barrow, F., DIETSCHE, K. B., Wang, H., Parthiban, P., Almutlaq, R. N., Adeyi, O. A., Herman, A., Bartolomucci, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.11.544503
“DISCUSSION Bariatric surgeries are the most effective options available for the treatment of obesity complications including MASLD and MASH 7, 8, 9, 47 .”
BackgroundSánchez, C. N. T. (2022) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/59942
New approaches in the diagnosis and treatment of non-alcoholic fatty liver disease.
Sergienko, O. I., Oparin, A. G., & Novokhatnya, А. E. (2023) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2023.02.012
Ткач, С. М., & Dogotar, V. B. (2023) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2023-2-34 · Cited by 1
“фіброзу у 84 % випадків, фіброз зменшився — у 70 %, причому це зменшення було прогресивним, починаючи з першого року після операції, і тривало протягом наступних 5 років [41].”
Stroh, C., & Luderer, D. (2023) · Diabetes aktuell · doi:10.1055/a-2116-9397
“Merke Verfahren mit duodenaler Exklusion wie der proximale Roux-en-Y-Magenbypass und der Single Anastomosis Gastric Bypass (MGB) weisen höhere Effekte auf die Remission des Diabetes mellitus Typ 2 und der nicht alkoholischen Fettleber auf als das rein restriktive Gastric Banding [9, 10].”
BackgroundInfluentialGuimarães, I. V., Freitas, D. S., & Rasera, I. (2023) · Research Society and Development · doi:10.33448/rsd-v12i8.43056
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4473-0
Clinical Guidelines on Nonalcoholic Fatty Liver Disease—Reply
Leung, P. B. K., Davis, A. M., & Kumar, S. R. (2024) · JAMA · doi:10.1001/jama.2024.0942
Paciente con alteración del perfil hepático y factores de riesgo metabólico
Barrio, M. D., Iruzubieta, P., Arias, M., & Crespo, J. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.04.003
Chierici, A. P., Fanny, F. O. U. R., Bulsei, J., Fontas, É., & Iannelli, A. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.04.019
RetractedСОВРЕМЕННЫЕ ПРИНЦИПЫ ЛЕЧЕНИЯ ЦИРРОЗА ПЕЧЕНИ И ЕГО ОСЛОЖНЕНИЙ
Бедельбаева, Г. Г., Рахметова, В. С., Камалова, Б. Б., Ужегова, Е. Б., & Ердаш, Б. Е. (2024) · Farmaciâ Kazahstana · doi:10.53511/pharmkaz.2024.80.59.001
Au, K., & Yang, W. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07430-y
“In a long-term follow-up of patients with MASH who undergo MBS, the resolution of MASH in liver samples from 84% of patients five years later [8].”
Billeter, A. T., & Müller-Stich, B. P. (2024) · Springer eBooks · doi:10.1007/978-3-662-58895-6_47
Choudhuri, G., Kalel, S. R., Sharma, Z. D., & Bansal, R. (2024) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2024.15.00585 · Cited by 1
Nonalcoholic fatty liver disease is a risk factor for cardiovascular disease
Li, Q. I. N., JunRu, W. U., YuQing, L. I. U., YingXuan, G. O. N. G., & JingJing, C. A. I. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0098
The Modulation of Gut Microbiota by Bariatric Metabolic Surgery and Its Role in NAFLD Treatment
郝, 小. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482288
Cirrhose métabolique : une entité en plein essor
Ratziu, V. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.11.012
L’arthrose chez le patient obèse : impact de la chirurgie bariatrique sur son évolution
Eymard, F., & Aron‐Wisnewsky, J. (2024) · Revue du Rhumatisme · doi:10.1016/j.rhum.2024.12.005
Current Standards in Therapeutic Management
Pustjens, J., & Brouwer, W. P. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_9
Histopathology of MASLD: Insights into Liver Tissue Changes
Francque, S., & Driessen, A. L. C. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_6
Wang, T. J., & Ryou, M. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-70004-0_7
Komissarova, M. Y., Maltsev, R. S., Filin, A. M., Алимов, М. М., Евдокимова, Н. В., & Новикова, В. П. (2025) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-229-9-75-85
覃, 胜. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153651
Xu, C., Zheng, Z., Yang, K. Y., Wu, R., Cao, J., & Duan, J. (2025) · Research Square · doi:10.21203/rs.3.rs-5880424/v1
Murray, J., Kefayat, A., Finlayson, M., Seenan, J. P., Hsu, R., & Din, S. (2025) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715251332318
Reiberger, T., Dominik, N., & Trauner, M. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.01.047
Stetson, A. E., Herdes, R. E., Kochis, M. A., Bizimana, C., Sy, M., Beltran, F., Nzenwa, I. C., Filho, J. C. J. P., Pratt, J. S. A., & Griggs, C. L. (2025) · Research Square · doi:10.21203/rs.3.rs-6480681/v1
Hépatopathies stéatosiques dysmétaboliques
Pariente, A. E. (2025) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(25)49520-9
The frontline of metabolic dysfunction–associated steatotic liver disease: More to be discovered
Ho, C.-T., Kao, W., & Su, C. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001266
Nonalcoholic Fatty Liver Disease
Choi, Y., & Feldstein, A. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11760-2.00075-6
Abnormalities of Carbohydrate Metabolism and the Liver
Brigham, D., & Sundaram, S. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11760-2.00074-4
Sleeve gastrectomy alleviates anxiety-like behaviors in mice with high-fat diet induced obesity
Wang, X., Zhang, Y., Zhang, C., Zhang, N., Yu, Y., & Liu, W. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.07.020
Combined Heart and Other Organ Transplants
KOBASHIGAWA, J. A., & Manla, Y. (2025) · Springer eBooks · doi:10.1007/978-3-031-88290-6_26
Long-Term Outcomes of Liver Pathology Following a Sleeve Gastrectomy
Brody, L., Randall, J. A., Khambaty, F., Young, R., Shah, P., & Reed, R. N. (2025) · Journal of Laparoendoscopic & Advanced Surgical Techniques · doi:10.1177/10926429251377372
Saviano, A., & Serfaty, L. (2025) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)46793-x
Interdisziplinäre Strategien zur Prävention und Therapie der MASLD
Roehlen, N., Laubner, K., Seufert, J., & Thimme, R. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2532-5919
Bozhko, A. O., Ananishnikova, E. A., Анатольевич, Ш. О., Koroleva, E. A., & Klimontov, V. V. (2025) · Kazan medical journal · doi:10.17816/kmj679721
Non-Alcoholic Fatty Liver Disease (NAFLD): A Review of Risk Factors, Pathogenesis, and Treatment
李, 春. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15113368
Wills, M. V., Mocanu, V., Elamin, D., Kachornvitaya, P., Barajas-Gamboa, J. S., Restrepo-Rodas, G., Aulestia, J., Corcelles, R., Allemang, M. T., Strong, A. T., et al. (2025) · Surgery · doi:10.1016/j.surg.2025.109966
Rinella, M., Cryer, D. R. H., Articolo, A., Fisher, T., Schneider, J., & Nadolsky, K. Z. (2022) · Figshare · doi:10.6084/m9.figshare.20282221
Abeysekera, K. W. M., Orr, J. G., Gordon, F. H., Howe, L. D., Hamilton-Shield, J. P., Heron, J., & Hickman, M. (2022) · Figshare · doi:10.6084/m9.figshare.20208307
Rinella, M., Cryer, D. R. H., Articolo, A., Fisher, T., Schneider, J., & Nadolsky, K. Z. (2022) · Figshare · doi:10.6084/m9.figshare.20282218
Hepatopatías esteatósicas dismetabólicas
Pariente, A. E. (2025) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(25)51059-0
Zhang, L., & Chen, H. (2025) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.141003
Lassailly, G., Pattou, F., & Mathurin, P. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.01.006
Self-citationJuárez-Sosa, J. M., Uribe, M., Montalvo-Jave, E. E., & Nuño‐Lámbarri, N. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.017 · Cited by 1
Tou, A. M., & Panganiban, J. A. (2026) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2026.115011
Sivakumar, W., O'Connor, D., Shabana, H., Crusher, R., Tuite, C., O’Sullivan, C., Houlihan, D. D., Stack, W., & O’Boyle, C. (2026) · Scientific Reports · doi:10.1038/s41598-026-39142-x · Cited by 1
“There is evidence to indicate that this is sustained with other studies reporting an advanced hepatic fibrosis resolution rate of 84% after 5 years 27 .”
Pu, Y., Cao, Z., Yang, S., Song, K., Chen, Y., Xu, J., Song, X., Fumpa, M., Du, Q., Wan, Q., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-025-08452-w
Liver Fibrosis Tests and Outcomes of Bariatric Surgery in Morbidly Obese Patients With MASLD
Prathyajuta, P., Prasoppokakorn, T., Thanapirom, K., Kachornvitaya, P., Sonsiri, K., Phathong, C., Khemtong, A., Udomsawaengsup, S., & Treeprasertsuk, S. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70034
Zhou, D., Ba, K., Jia, T., Shen, Y., & Yang, L. (2026) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/cjgh/8512168
“However, the generalizability of these fndings to patients with established decompensated cirrhosis is limited, as the study population was predominantly noncirrhotic, and bariatric surgery is often contraindicated in advanced liver disease [73].”
Pan, Y., Qu, Y., Ma, H., Wang, M., Zhong, M., & Hu, S. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1780788
Abdou, H. A., & Omar, S. A. (2026) · ASIDE Gastroenterology · doi:10.71079/aside.gi.031826446
“%) yields more robust benefits, including regression of fibrosis [137, 138].”
Fibrose hépatique : physiopathologie, diagnostic, pronostic
Gilgenkrantz, H., Bédossa, P., & Pol, S. (2026) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)43565-7
Rôle de REG3A dans la maladie métabolique du foie d'origine nutritionnelle
Nguyen, T.-S. (2024) · theses.fr (ABES) · doi:10.70675/2c0ffdcfz96ccz43b0z8e03zb358f83e528d
Morisseau, L. (2023) · theses.fr (ABES) · doi:10.70675/cfa5953ez697dz47bez9768zde0845d5a7b8
Calorie restriction mitigates steatotic liver disease in obese rats after bariatric surgery
Lin, Y., Wu, C.-Y., Hsieh, Y.-R., Lin, Y.-T., Wang, W., Chang, C.-C., Huang, S., & Kao, W. (2026) · Nutrition Research · doi:10.1016/j.nutres.2026.04.011
Younus, H., Nawaz, A., & Khwaja, H. A. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1015289
Njeim, R., Abureesh, O., Sohail, A., Tam, R., & Deeb, L. S. (2026) · Livers · doi:10.3390/livers6030035
“Sustained lifestyle modification requires behavioral support through structured programs; for patients unable to achieve adequate weight loss, pharmacotherapy or bariatric surgery may be considered, with the latter demonstrating durable histological improvements in selected candidates [27].”
REDUÇÃO DE COMORBIDADES DEVIDO A PROCEDIMENTOS INVASIVOS VOLTADOS PARA PERDA PONDERAL
de Freitas, M. C., dos Santos, R. A., Baccarin, C. S., Gigueira, F. M., Lima, A. L. S., Apuzzo, E., Ferreira, K. D. S., & Molina, I. (2026) · Aracê. · doi:10.56238/arev8n5-030
Baron, A., Tron, L., Balusson, F., Zannou, V., Mignot, V., Ego, A., Borowick, A., Decaens, T., Oger, E., Bailly, S., et al. (2026) · JMIR Research Protocols · doi:10.2196/89577
“Even after CLD has developed, controlling the underlying causes can slow disease progression to advanced fibrosis stages and/or PLC, thereby reducing liver-related and overall mortality [11,29-32].”
Liver Transplantation in the Era of Metabolic Bariatric Surgery: A Bibliometric Analysis
Yasheng, R., Azhati, Y., Wu, J., Abudukadi, G., He, R.-D., Tulading, A., Mamuti, A., Maimaiti, M., Lv, C.-H., Wang, M.-J., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08796-x
“MBS has been proven to significantly improve obesity-related liver conditions such as NAFLD and NASH [62 , 63 ], which are rising in prevalence and have become one of the most common causes of ESLD [ 7].”
General Indications and Contraindications for Metabolic/Bariatric Surgery (MBS)
Atkinson, R. B., Rojas-Alexandre, M., & Shikora, S. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_9
Sheerali, A. (2026) · Research Square · doi:10.21203/rs.3.rs-9918447/v1
Prada, S., Penaforte, R., Pereira, B. S., Major, M. F., & Aldomiro, F. (2026) · Cureus · doi:10.7759/cureus.112698
Navas, H. J. G., Dahlgren, N., Bhatia, S., Hanipah, Z. N., Galvani, C. A., Cook, M. W., Danos, D., Schauer, P. R., & Albaugh, V. L. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.07.009
Bariatric surgery resolves MASH by enhancing MAT1A-dependent one-carbon metabolism
Tang, B., Shen, Q., Yuan, J. P., Huang, X., Shao, Y., zhu, N., Guo, H. H., Cao, H., Wang, H., Wang, H. W., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75822-y
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.06.013
Self-citationBeyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology
Crespo, J., Alonso‐Peña, M., Jiménez-González, C., Cayon, L., & Iruzubieta, P. (2026) · Pharmaceuticals · doi:10.3390/ph19081145
Vozza, A., Biagi, F., Chiara, R., Vizzutti, F., & Marra, F. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04456-1 · Cited by 1
“When compared with bariatric surgery, GLP-1RA therapy generally yields smaller effects on weight loss, insulin resistance, and histological resolution of steatohepatitis [55–58] which may translate into a comparatively lower magnitude of protection against cirrhosis progression and HCC.”
Adipose Tissue Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
Cruz, A. J. L., & Yuan, L. (2026) · Cells · doi:10.3390/cells15151377
“Among weight-mediated interventions, bariatric surgery has produced the largest reported histologic effect in MASH: in a prospective 5-year follow-up by Lassailly and colleagues, NASH resolved without worsening fibrosis in 84% of patients with paired biopsies and fibrosis improved in 70% [102].”
Effects of bariatric surgery on non-invasive markers of MASLD: a retrospective analysis
Lukolic, I., Khan, J., McCabe, M., Jibran, M., Hamza, M., Rojony, R., Ismail, S., Patel, D. M., & Maheshwari, A. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-05187-5
“Over 50% would have been excluded using FIB-4 alone, demonstrating poor correlation with histology [7, 14, 19, 20].”
Selection of Patients for Sleeve Gastrectomy. Indications and Contraindications
Pedrique, M. M., Oliveros, A. A., Casanova-Aparicio, A., Carrillo, G. A., Jodrá, V. V., & Ruíz-Tóvar, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-25644-7_2
Hepatic Mitochondrial Alterations in GLP-1 Poor Responders Undergoing Roux-en-Y Gastric BypassPreprint
Pratap, A., Juda, B., Bessesen, D., Gilden, A., Westbrook, L., Janetsko, J., Monge, K. M., Dareshouri, A., Idrovo, J. P., Rothchild, K. B., et al. (2026) · medRxiv · doi:10.64898/2026.08.04.26359613
Xu, Y., Gong, F., Cao, T., Chen, R., Zhuo, N., Wei, Y., & Yang, Y. (2026) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/14703203261477614
Bernardes, C. D. O., Lins, E. M., Rocha, F. A., Kreimer, F., Silva, R. B. V., de Medeiros, N. R. F. C., Ferreira, K. M. L. D. M., & Ferraz, Á. A. B. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08891-z
“In a prospective study with sequential liver biopsies, Lassailly et al. reported MASH resolution without worsening fibrosis in 84% of patients five years after surgery, with progressive fibro - sis regression over time [28].”
Evolving indications for metabolic and bariatric surgery
Wills, M. V., & Corcelles, R. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.009
Bulsei, J., Carandina, S., Zulian, V., Fontas, É., & Iannelli, A. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000005584
Therapie metabolischer Lebererkrankungen
Huttasch, M., & KAHL, S. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01502-6
Metadata
- Authors
- Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., Dharancy, S., Pattou, F., & Mathurin, P.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Pattou, François
- Mathurin, Philippe
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 159
- Issue
- 4
- Pages
- 1290-1301.e5
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W3034346518
- Cited by
- 622
- References
- 27
- Citations by year
- 2026: 93 · 2025: 105 · 2024: 109 · 2023: 106 · 2022: 108 · 2021: 89 · 2020: 11
- FWCI
- 56.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion, other-oa)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- HAL (submittedVersion)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
- Funders
- European Regional Development Fund
- Agence Nationale de la Recherche (ANR-10-LABX-46, ANR-16-RHUS-0006)
- Ministère des Affaires Sociales et de la Santé
- European Commission
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Keywords
- bariatric surgery, nonalcoholic steatohepatitis, liver fibrosis regression, obesity, long-term outcomes, weight loss, NASH resolution, liver biopsy histology, bridging fibrosis, metabolic surgery, liver cancer risk, liver transplantation risk
- MeSH terms
- Adult, Biopsy, Female, Follow-Up Studies, France, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Obesity, Morbid, Prospective Studies, Remission Induction, Time Factors, Weight Loss, Treatment Outcome, Bariatric Surgery, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
